GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » Price-to-Owner-Earnings

Xvivo Perfusion AB (Xvivo Perfusion AB) Price-to-Owner-Earnings : (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB Price-to-Owner-Earnings?

As of today (2024-06-08), Xvivo Perfusion AB's share price is $43.09. Xvivo Perfusion AB does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Xvivo Perfusion AB's Price-to-Owner-Earnings or its related term are showing as below:


XVIPF's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 31.925
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-08), Xvivo Perfusion AB's share price is $43.09. Xvivo Perfusion AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.32. Therefore, Xvivo Perfusion AB's PE Ratio for today is 134.66.

As of today (2024-06-08), Xvivo Perfusion AB's share price is $43.09. Xvivo Perfusion AB's EPS without NRI for the trailing twelve months (TTM) ended in was $0.32. Therefore, Xvivo Perfusion AB's PE Ratio without NRI for today is 134.66.

During the past 12 years, Xvivo Perfusion AB's highest PE Ratio without NRI was 11812.50. The lowest was 76.10. And the median was 294.87.


Xvivo Perfusion AB Price-to-Owner-Earnings Historical Data

The historical data trend for Xvivo Perfusion AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Price-to-Owner-Earnings Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xvivo Perfusion AB's Price-to-Owner-Earnings

For the Medical Devices subindustry, Xvivo Perfusion AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Price-to-Owner-Earnings falls into.



Xvivo Perfusion AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Xvivo Perfusion AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=43.09/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (OTCPK:XVIPF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Xvivo Perfusion AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (Xvivo Perfusion AB) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.